Fortekor Flavour 5 mg Tablets for Cats and Dogs

Dogs;
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea, Vomiting,
Anorexia, Fatigue
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
Incoordination,
In dogs with chronic kidney disease, the product may increase plasma creatinine concentrations
at the start of therapy. A moderate increase in plasma creatinine concentrations following
administration of ACE inhibitors is compatible with the reduction in glomerular hypertension
induced by these agents and is therefore not necessarily a reason to stop therapy in the absence
of other signs.
In double-blind clinical trials in dogs with congestive heart failure, the veterinary medicinal
product was well tolerated with an incidence of adverse reactions lower than observed in
placebo-treated dogs.
Cats:
Rare
(1 to 10 animals / 10,000 animals treated):
Diarrhoea Emesis,
Anorexia, Dehydration, Lethargy
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
Increased appetite, Weight gain

Revised: June 2025
AN: 00325/2025Page 3 of 71
In cats with chronic kidney disease, the productmay increase plasma creatinine concentrations at
the start of therapy. A moderate increase in plasma creatinine concentrations following
administration of ACE inhibitors is compatible with the reduction in glomerular hypertension
induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence
of other signs.

Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for respective contact details.